Innovative Drug Discovery ExcepGen leverages engineered human cell lines to produce full-length human proteins, positioning it as a key partner for biotech and pharma companies seeking advanced tools for drug discovery and biologics development.

Strong Industry Collaborations Having launched with partners from large pharmaceutical companies and securing investment from ZAKA VC and RA Capital Management, ExcepGen's strategic alliances suggest opportunities for joint development and licensing deals.

Growing Funding Momentum With recent funding rounds totaling $4 million and backing from notable investors, ExcepGen is positioned for expansion, offering avenues for investment and collaborative research projects with emerging biotech firms.

Niche Focus on Biologics Specializing in biologics production technologies, ExcepGen's expertise aligns well with companies focused on biologics pipelines, presenting sales opportunities for research tools and bespoke production services.

Emerging Market Presence As an early-stage company in the competitive biotech research industry, ExcepGen's innovative technologies and strategic partnerships create potential entry points for enterprise solutions, licensing of proprietary platforms, and collaborative ventures.